Friday, 17 September 2021 | 08:24 WIB

GlaxoSmithKline and CureVac Collaborate on Next Gen Covid-19 Vaccine Variants

GlaxoSmithKline and CureVac Collaborate on Next Gen Covid-19 Vaccine Variants (fxempire)

JAKARTA, NETRALNEWS.COM - Britain-based GlaxoSmithKline (GSK) and CureVac biotechnology from Germany have signed a contract worth 150 million euros (about IDR2.5 trillion) to develop the upcoming generation of COVID-19 vaccines that targets several variants in one product.

Through the joint statement on Wednesday, the partnering companies targeted a possible product launching by 2022.

GSK, which also owns shares in CureVac, will also support the production of the first 100 doses of CureVac COVID-19 vaccine candidate in 2021, the company said on Wednesday (02/03/2021).

For GSK, the world’s biggest vaccine producer according to sales, the plan is to mark the new effort to play a relevant role in fighting against the pandemic, after a COVID-19 alliance with Sanofi is suspended due to postponed development, and after a similar alliance with China Clover Biopharmaceuticals ended, as reported by Antara.